https://www.linkedin.com/posts/basilardbiotech_basilard-biotech-the-makers-of-celletto-activity-7335345760730812416-TVfH?utm_source=li_share&utm_content=feedcontent&utm_medium=g_dt_web&utm_campaign=copy
Basilard BioTech, the makers of Celletto™ (currently a 2nd generation working prototype out for industry validation), our superior nanoneedle and microfluidics-based nonviral gene delivery technology platform, are pleased to welcome our new Board Director, Brad Glover.
I stumbled across this on linkedin from recent activity liked by Garrett Gincley Vice President, Quality and Cell Therapy External Manufacturing at Imugene. I wonder if there are future implications to partner/collaborate with imugene Azer-cel.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $112.0M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.6¢ | 1.4¢ | $125.4K | 8.369M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 76 | 17029463 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 1061875 | 3 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |